TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES
Abstract: Approved uses of intravenous IgG suspensions (IgGiv) are agammaglobulinemias, immune thrombocytopenia, rheumatoid arthritis, Guillán-Barré syndrome, myasthenia gravis, multiple sclerosis. IgGiv is proposed as an immunomodulatory agent in reproductive failures since it has been used to eval...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Escuela de Salud Pública y Ambiente. Fac. Cs. Médicas UNC
2017
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/RSD/article/view/17144 |
| Aporte de: |
| Sumario: | Abstract: Approved uses of intravenous IgG suspensions (IgGiv) are agammaglobulinemias, immune thrombocytopenia, rheumatoid arthritis, Guillán-Barré syndrome, myasthenia gravis, multiple sclerosis. IgGiv is proposed as an immunomodulatory agent in reproductive failures since it has been used to evaluate rates of newborns in women with repeated failures in implantation (RFI) and recurrent abortions (RAb). However, this indication is not specified in the package leaflet (“off-label use”). Between 2010 and 2015, anamnesis and complete reproductive history were performed on 2333 couples, evaluating several factors. Of 447 pregnancies, 143 patients received IgGiv UNC treatment. 79 consulted for RAb (55%) and 64 for RFI (45%). The diagnosis of Hashimoto’s thyroiditis was positive in 91 patients (64%). In 3 patients (2%) there were adverse reactions. Live newborns were 83, success rate 58%. This high rate and the absence of adverse reactions are evidences of effectiveness and safety of IgGiv |
|---|